Launch of Rydapt®
Ever heard of advanced systemic mastocytosis (advSM)? No? Then you are not alone. This cancer is a group of rare diseases of the mast cells. Our customer Novartis has put the task of launching Rydapt®, a treatment drug for advSM patients, onto the market into our capable hands.
Further communication components include the trade fair multi-touch app, events showcasing and giveaways that reinforce the message.
Besides the successful market launch, which exceeded all expectations, we are particularly delighted about the fact that information is now available for the first time to advSM patients. This is in the form of comprehensive website content and a brochure. We also managed to raise awareness among referring physicians and primary treatment providers of this rare disease.